With pos­i­tive key tri­al, Kala Phar­ma's dry eye drug Ey­su­vis em­u­lates ap­proval path set by Xi­idra

Mixed da­ta from pre­vi­ous study read­outs on its drug for short-term dry eye re­lief pre­cip­i­tat­ed a re­jec­tion from the FDA, leav­ing Kala Phar­ma­ceu­ti­cals’ fate in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER